

1 Targeting mutant TNNT2-induced epigenetic perturbation and pathogenic 2 signaling in left ventricular non-compaction cardiomyopathy

3
4 **Authors:** You-Yi Li^{1†}, Wei-Chieh Tseng^{2†}, Hua-Ling Kao¹, Yu-Shin Shie¹, Sheunn-Nan Chiu²,
5 Ya-Ting Wu¹, Chung-Ming Sun³, Shiou-Ru Tzeng⁴, Liang-Chuan Lai⁵, Miao-Hsia Lin⁶, Yen-
6 Wen Wu⁷, Kuan-Yin Ko⁷, Jyh-Ming Jimmy Juang⁸, Ryan Hsieh⁹, Mei-Hwan Wu^{2*}, Wen-Pin
7 Chen^{1*}, Hong-Nerng Ho^{10,11}

8 **Affiliations:**

9 ¹Graduate and Institute of Pharmacology, College of Medicine, National Taiwan University;
10 Taipei, Taiwan.

11 ²Department of Pediatrics, National Taiwan University Hospital and Medical College, National
12 Taiwan University; Taipei, Taiwan.

13 ³Department of Applied Chemistry, National Yang Ming Chiao Tung University; Hsinchu City,
14 Taiwan.

15 ⁴Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan
16 University; Taipei, Taiwan.

17 ⁵Graduate Institute of Physiology, College of Medicine, National Taiwan University; Taipei,
18 Taiwan.

19 ⁶Graduate Institute of Microbiology, College of Medicine, National Taiwan University; Taipei,
20 Taiwan.

21 ⁷Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan
22 University College of Medicine; Taipei, Taiwan.

23 ⁸Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital
24 and Medical College, National Taiwan University; Taipei, Taiwan.

25 ⁹Department of Mathematics, Durham University, Durham, United Kingdom.

26 ¹⁰Department of Obstetrics and Gynecology, National Taiwan University Hospital and
27 Medical College, National Taiwan University; Taipei, Taiwan.

28 ¹¹Taipei Medical University; Taipei, Taiwan.

29
30 †These authors contributed equally to this work.

31 *Corresponding author. Email: chenwenpin@ntu.edu.tw

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Author contributions:

Conceptualization: W.P.C., W.M.H.
Methodology: W.P.C., W.M.H., H.H.N., Y.Y.L., W.C.T., J.M.J.
Chemical synthesis: C.M.S.
Computer simulations of the protein structure: S.R.T.
Investigation: Y.Y.L., W.C.T., S.N.C., H.L.K., Y.S.S., Y.J.K., Y.Y.W., K.Y.K.,
Y.T.W., A.D.L., K.Y.K., Y.W.W.
Data analysis: L.C.L., M.H.L., Y.Y.L., W.P.C., W.C.T., H.L.K., R.H.
Clinical examination & echocardiography: W.C.T., S.N.C., M.H.W.
Funding acquisition: W.P.C., W.M.H., H.H.N.
Project administration: Y.Y.L., W.C.T.
Writing – original draft: Y.Y.L., W.C.T., W.P.C.
Writing – review & editing: W.P.C., W.M.H., H.H.N.

Conflict-of-interest statement: The authors have declared that no conflict of interest exists.

1 **Abstract**

2 **Background**

3 Compound mutations of *TNNT2*^{R141W/+} (encoding troponin T) and *MYPN*^{S1296T/+} (encoding
4 myopalladin) are associated with familial left ventricle non-compaction cardiomyopathy (LVNC).
5 However, it remains unclear in which would be the pathogenic mutation, the underlying
6 mechanism, and the target therapy for LVNC.

7 **Methods**

8 Knock-in C57BL/6J mice harboring mutations in orthologous genes in *Tnnt2*^{R154W} or/and
9 *Mypn*^{S1291T} and human cardiomyocytes derived from iPSC of healthy donors and LVNC patients
10 (LVNC-hCM) were employed for disease modeling, omics analysis, mechanistic study, and drug
11 development.

12 **Results**

13 Using knock-in mice for disease modeling, it was clarified that the orthologous mutation in *Tnnt2*,
14 but not in *Mypn*, led to cardiac hypertrabeculation, noncompaction, and heart failure. 3D protein
15 structure modeling by Swiss-model found a loss of slat bridge between TNNT2(R141W) and E-
16 257 in tropomyosin, contributing to the decreased cardiac contraction. Further mechanistic study
17 discovered that troponin T (TNNT2) appears to function as an HDAC1 sponge in cardiomyocyte
18 nuclei. The compromised association between nuclear TNNT2(R141W) and HDAC1 causes
19 cardiac epigenetic perturbation and subsequently leads to transcriptional dysregulation. The
20 downregulation of cardiac muscular genes was concomitant with the impairment of cardiac
21 contraction, which would be partially rescued by pan HDAC inhibitor. Besides, the upregulation
22 of TGFβ-signaling molecules and EZH2 did contribute to cardiac growth defects, which were

1 mitigated by TGF β R1 inhibitor (A83-01) and EZH2 inhibitor (GSK503), respectively.
2 Simvastatin, a hit drug identified from the repurposed drug screening, can restore nuclear
3 TNNT2(R141W)-HDAC1 association, thereby recovering cardiac epigenetic, translational
4 profiles, growth and function in LVNC-hCM *in vitro* and cardiac function in LVNC mice
5 harboring *Tnnt2*^{R154W} *in vivo*. The cardiac function was significantly improved in the proband
6 receiving 5 mg once daily for consecutive two years.

7 **Conclusion**

8 Mutant TNNT2(R141W) diminished its nuclear HDAC1 sponge function in cardiomyocyte to
9 induce LVNC pathogenesis through perturbing cardiac epigenetic and the gene expressions.
10 Targeting to HDAC, TGF β , EZH2 may rescue part of cardiac pathological signaling. Simvastatin
11 can act as a chemical chaperone to comprehensively recover cardiac epigenetic via restoring
12 nuclear TNNT2(R141W)-HDAC1 association.

13

14

15

16

17

18

19

20

21

1 **Introduction**

2 Left ventricular non-compaction cardiomyopathy (LVNC) is characterized by a spongy left
3 ventricular (LV) myocardium featuring abnormal trabeculations particularly in the left
4 ventricular apex.^{1, 2} A population study found the mean annual incidence of newly diagnosed
5 cases was 0.11 per 100,000 for children aged < 10 years and was highest in the first year of life
6 (0.83 per 100,000 infants).³ The survival rate, unmarked by death or transplantation, stands at a
7 mere 48% a decade following the diagnosis. Notably, patients who manifest symptoms during
8 early infancy with a dominant dilated phenotype exhibit even graver long-term outcomes.³
9 Genetic mutations associated with LVNC encompass variations in MIB1⁴ and TBX20⁵, TAZ⁶,
10 LMNA⁷, NUMB/NUMBL⁸, mitochondrial genome mutations (distal 22q11·2⁹), and the
11 sarcomere-encoding genes (MYH7, ACTC1, TNNT2, MYBPC3, TPM1, LDB3, and TNNT3¹⁰).
12 Nevertheless, the comprehensive mechanisms underlying the contribution of various genetic
13 mutations to LVNC pathogenesis remain subject to further elucidation.

14 The dysregulation of Notch signaling, such as inactivation of cardiac Mib1, myocardial
15 Jagged1, or endocardial Notch1⁴ along with the sustained upregulation of MFng and Dll4¹¹, can
16 precipitate premature trabeculation and myocardial non-compaction during the embryonic
17 development of mice hearts. Conversely, the aberrant activation of TGF- β signaling, induced by
18 mutant TBX20, has been observed to impede myocyte proliferation in mice embryonic
19 myocardium, ultimately leading to LVNC¹². Furthermore, cardiometabolic dysfunction had been
20 identified as a constituent of the pathophysiological processes contributing to LVNC¹³.
21 Nonetheless, the precise mechanism through which mutant sarcomere genes influence
22 cardiomyocyte proliferation and myocardial compaction remain elusive.

1 In our investigations, we encountered a LVNC family simultaneously harboring mutations
2 in $TNNT2^{R141W/+}$ and $MYPN^{S1296T/+}$. Despite the administration of leading-edge pharmaceutical
3 interventions, including anti-congestive agents, diuretics, renin angiotensin blockade, beta-
4 blockers, or mineralocorticoid receptor antagonists as well as antiplatelet or anticoagulation
5 therapy to prevent thromboembolism^{2, 14, 15}, the prognosis remained unfavorable. Mechanical
6 circulatory support by devices, such as LV assist device, and cardiac transplantation, while
7 considered as a therapeutic option for individuals resistant to pharmacotherapy¹⁶, frequently
8 faces constraints stemming from limited donor resources.^{1, 3} Thus, we embarked on an integrated
9 protocol that encompasses genetic characterization, disease modeling by knock-in mice
10 harboring mutant genes, hiPSC modeling, omics study, and drug repurposing screening, with the
11 aim of elucidating potential mechanisms-driven therapeutic strategies.

12

13

14

15

16

17

18

19

20

21

1 **Methods**

2 ***1. Identify the index LVNC family with genetic information***

3 LVNC patients who had advanced heart failure for more than 3 months during the infancy
4 were enrolled (Figure 1A & supplementary Figure 1). Whole exon sequencing was performed
5 to find out the genetic mutations, which were further confirmed by Sanger sequencing.

6 From such a LVNC family, we identified two heterozygous missense mutations in TNNT2
7 (chr. 1:201333464 G>A; p.R141W) and MYPN (chr. 10: 68210378 A>T; p.S1296T) in the
8 proband and her father.

9 ***2. Human induced pluripotent stem cell (hiPSC) study***

10 Human induced pluripotent stem cell (hiPSC) lines derived from LVNC patients (the proband:
11 iH-LVNC-hiPSC, her father: iF-LVNC-hiPSC; the pedigree in Figure 1A &
12 echocardiography in supplementary Figure 1), normal healthy woman (her mother: iM-
13 hiPSC), and a normal healthy man (deidentified patient: health m-hiPSC) were reprogrammed
14 from peripheral blood monocytes (PBMCs) of the same patient by Sendai virus carrying four
15 Yamanaka factors (CytoTune-iPSC 2.0 Sendai Reprogramming kit, Thermo Fisher Scientific
16 Inc., MD, USA). All clinical investigations have been conducted according to the Declaration
17 of Helsinki principles. All human studies have been approved by Research Ethics Committee
18 D of the National Taiwan University Hospital. The proband's informed consent was obtained
19 from her parents. Chromosome analysis of hiPSC lines was performed by karyotyping
20 (supplementary Figure 2). The hiPSC lines were cultured by monolayer in Matrigel-coated
21 dishes and maintained in an Essential 8 culture medium (Thermo Fisher Scientific Inc., CA,
22 USA) containing bFGF (10 ng/mL). Cardiomyogenic differentiation was conducted by the
23 modified protocol of the chemically defined conditions¹⁷ based on the RPMI 1640 medium.

1 In brief, CHIR99021 (6-12 μ M) was placed in RPMI 1640 medium containing B27 Insulin
2 minus supplement (RPMI/B27/I-, Thermo Fisher Scientific Inc., CA, USA) to induce
3 mesoderm differentiation for two days. Then, the hiPSC differentiation medium was changed
4 to RPMI/B27/I- containing IWP-4 (5 μ M) to induce cardiomyogenic differentiation for the
5 next two days. The differentiated cells were maintained in the RPMI/B27/I- medium until the
6 presence of the beating myocytes around days 9-12 after differentiation. Cardiomyocytes
7 derived from hiPSC (hiPSC-hCM) were further enriched by metabolic selection with glucose-
8 free RPMI medium containing lactate (4 mM). The purity of cardiomyocytes was
9 meticulously assessed through immunocytochemistry. Staining was conducted employing a
10 mouse monoclonal antibody specific to sarcomeric actinin α (SA, Sigma-Aldrich), succeeded
11 by the secondary antibody, Alexa Fluor 488-conjugated goat anti-mouse IgG. As a negative
12 control, staining with Alexa Fluor 488 goat anti-mouse IgG alone was employed.
13 Subsequently, the labeled cells underwent analysis using the BD LSRFortessa cell analyzer.
14 For advanced experiments, only cell batches with a purity exceeding 90% of SA+
15 cardiomyocytes were employed. SA+ cardiomyocytes were subsequently reseeded onto
16 Matrigel-coated dishes/plates and maintained in RPMI 1640 medium supplemented with B27
17 for the specified experiments.

18 **3. LVNC mouse model and the cardiac function imaging**

19 The homologous loci of human *TNNT2*^{R141W} and *MYPN*^{S1296T} were equal to murine *Tnnt2*^{R154W}
20 and *Mypn*^{S1251T}. Therefore, the orthologous *Tnnt2*^{R154W/+} and *Mypn*^{S1291T/+} knocked-in mice on
21 C57BL/6j background were generated by Gene Knockout Mouse Core Laboratory of National
22 Taiwan University Center of Genomic Medicine. Genetically homozygous *Tnnt2*^{R154W/R154W}
23 (*Tnnt2*^{R154W}) and *Mypn*^{S1291T/S1291T} (*Mypn*^{S1291T}) were obtained from intrastain crossing

1 *Tnnt2*^{R154W/+} and *Mybn*^{S1291T/+} mice, respectively. Genetically heterozygous
2 *Tnnt2*^{R154W/+}::*Mybn*^{S1291T/+} LVNC mice were obtained from crossing *Tnnt2*^{R154W/+} and
3 *Mybn*^{S1291T/+} mice. PCR and DNA sequencing were performed to confirm the genotype. All
4 animal procedures and protocols followed the US National Institutes of Health and European
5 Commission guidelines and were approved by Institutional Animal Care and Use Committee
6 (IACUC) of National Taiwan University College of Medicine and College of Public Health.
7 All animal experiments were conducted at an AAALAC-accredited facility.
8 Drug administration (Simvastatin: 8·27 μmol/kg/day; DMSO: 3·6 μL/day) was conducted by
9 the implantation of an osmotic infusion pump (ALZET model 2006, Durect Corp. Cupertino,
10 CA, USA) to the subcutaneous space of LVNC mice's backs at the indicated age in the results.
11 For continuous drug administration during day 1-126, the vehicle- or simvastatin-containing
12 pump was replaced with a new one for every 42 days. Cardiac motion function of LVNC mice
13 was measured by Prospect T1 echocardiography imaging system (Scintica Instrument, Inc.,
14 Webster, TX, USA) in M-mode under anesthetization by 1-2% isoflurane inhalation.

15 **4. Immunocytochemistry and flow cytometric analysis (FACS)**

16 EdU pulse-chase labeling was performed in hCM during day 12-16 after myogenic
17 differentiation by Click-it Plus EdU conjugated with Alexa Fluor 594 or Alexa Fluor 647 flow
18 cytometry assay kit (ThermoFisher Scientific, CA, USA). Cells were co-stained with mouse
19 monoclonal antibody against sarcomeric actinin α (Sigma-Aldrich) in combination with rabbit
20 polyclonal antibody against DLL4 (Genetex) or JAG1 (Abcam). The details of antibodies
21 were listed in supplementary Table 1. The samples were followed by staining with secondary
22 antibodies of Alexa Fluor 488 goat anti-mouse IgG and Alexa Fluor 594 donkey anti-rabbit
23 IgG. The labeled cells were analyzed by BD LSRFortessa cell analyzer.

1 **5. Pull-down assay and liquid chromatography-tandem mass spectrometry (LC-MS/MS)**

2 The ORF of *TNNT2* coding either the wild type (WT) or missense mutation (R141W) was
3 recombined to multiple cloning site (MCS) of pDEST-flag-SBP-MCS (supplementary
4 Figure 3). Plasmid of either pDEST-*TNNT2* or pDEST-*TNNT2*^{R141W} was transfected to
5 healthy-hCM or LVNC-hCMs by Lipofectamine 3000 (Invitrogen, Life technologies) in Opti-
6 MEM (GIBCO, Life Technologies) on day 14 after myogenic differentiation. The proteins
7 associated with the fusion proteins of flag-SBP-*TNNT2* or -*TNNT2*^{R141W} were pulled down by
8 Dynabeads® M-280 Streptavidin (Invitrogen, Life technologies). *TNNT2*-associated proteins
9 were identified by LC-MS/MS (Orbitrap Fusion Lumos with ETD, Thermo Fisher Scientific
10 Inc.) and were further validated by western blot or PLA assay.

11 **6. Immunofluorescence (IF) or immunohistochemistry (IHC)**

12 Mice E15.5 embryo or adult mice hearts were harvested from mice under anesthetization by
13 3-5 % isoflurane inhalation. After washing out blood, the embryo or heart was fixed by 4%
14 paraformaldehyde on ice for 3h. Then, it was washed out by DPBS for three times. The
15 samples were first incubated in 35 % sucrose until sedimentation, then embedded in OCT and
16 stored at -80°C freezer before making cryosections with a thickness of 8 µm. After washing
17 out OCT, the sections were further used for H&E stain, Masson's trichrome stain or
18 immunofluorescence stain followed by sequential staining with primary antibodies, including
19 mouse monoclonal antibody against sarcomeric actinin α (Sigma-Aldrich), phospho-histone
20 3 (phospho-S10, Abcam), and the corresponding secondary antibody (Alexa Fluor 488
21 conjugated goat anti-mouse IgG & Alexa fluor 594 conjugated donkey anti-rabbit IgG). The
22 details of antibodies were listed in supplementary Table 1. DAPI is used for nuclear

1 counterstain. Fluoromount-G mounting medium (Invitrogen) was used to mount slides. The
2 fluorescent images were acquired by LSM 880 confocal microscope system.

3 **7. Immunoprecipitation (IP)**

4 Mice ventricle tissue was cut into small pieces and homogenized in the homogenizer. Extracted
5 cytosol and nuclei part lysate with the nuclear extraction kit (Abcam). Immunoprecipitation of
6 Lamin B1 (1:250, GeneTex) or HDAC1 (1:250, GeneTex) using Pierce Crosslink Magnetic
7 IP/Co-IP kit (ThermoFisher scientific) and immunoblot target antigen TNNT2 (1:20000,
8 GeneTex) was subquentially performed.

9 **8. Proximity ligation assay (PLA)**

10 Mice hearts were fixed by 4% paraformaldehyde (PFA) on ice for 3h. After washing out PFA,
11 mice hearts were immersed in 35 % sucrose until sedimentation at 4°C. Then the heart was
12 embedded in OCT and was stored at -80 °C until the manufacture of frozen sections with the
13 thickness of 8 µm. After OCT removal by PBS and antigen retrieval by HistoReveal (Abcam),
14 cardiac sections were blocked by Donkey anti-mouse IgG (1:40 in PBS containing 0.1 % Triton
15 X-100, overnight at 4 °C). After washing out, cardiac sections were incubated in PBS
16 containing dual-stain primary antibody cocktail: (1) mouse monoclonal antibody against
17 troponin T (1:500, GeneTex) and rabbit polyclonal antibody against HDAC1 (1:300, GeneTex),
18 or (2) mouse monoclonal antibody against troponin T (1:500, GeneTex) and rabbit polyclonal
19 antibody against Lamin B1 (1:100, GeneTex) at 4°C overnight. After the primary antibodies
20 were washed out with PBS for three times, Duolink PLA Fluorescence kit (Sigma-Aldrich) was
21 used to identify the colocalization of the proteins in interest listed above by following the
22 manufacturer's instructions. DAPI was used as the nuclear counterstain. High resolution of PLA
23 image was acquired by LSM880 confocal microscope system in Airyscan mode with 3D Z-

1 stack for the advanced analysis of the localization/distribution and the volume of PLA spot by
2 Imaris Surfaces (Oxford Instruments plc, Tubney Woods, Abingdon, Oxon OX13 5QX, UK).

3 **9. Measurement of myocyte contraction and intracellular calcium transient**

4 Myocyte shortening was measured by IonOptix myocyte contractility system (IonOptix LLC.,
5 MA, USA) with electrical pacing at 1 Hz in the absence or presence of isoprenaline at the
6 concentrations of 0.03, 0.3 and 1 μ M and was shown as the percent shortening of the cell
7 length. Intracellular calcium transients were recorded under optical pacing at 1 Hz by the high-
8 content imaging system in hiPSC-hCM expressing GECIs (genetically encoded calcium
9 indicator) and ChR2-K-GECO (channelrhodopsin-2) delivered by lentivirus and AAV,
10 respectively¹⁸. Cells were kept in the system with 5% CO₂ supplementation at 37 C for 2 h
11 equilibrium before recording and were optically paced at 1 Hz.

12 **10. Omics study**

13 **Proteome analysis**

14 The total proteins of hiPSC-derived cardiomyocytes treated with or without simvastatin were
15 extracted by RIPA buffer containing protease and phosphatase inhibitor cocktails (Thermo
16 Fisher Scientific Inc., USA). The samples were further digested by trypsin. After the samples
17 were desalted and dried, LC-MS/MS analysis was performed by LTQ-Orbitrap Velos mass
18 spectrometer system. The peptide and protein group IDs were obtained by MASCOT database
19 searching with precursor mass accuracy of 7 ppm and MS/MS accuracy of 0.5Da. The large
20 mass-spectrometric raw data were further analyzed by MaxQuant software based on the
21 Uniprot human database with label-free quantification method and followed by the statistical
22 analysis using Perseus software.

23 **Transcriptome analysis**

1 The total RNAs of mice hearts or hiPSCs derived cardiomyocytes were extracted by TRIzol
2 reagent (Invitrogen, Thermo Fisher Scientific Inc., USA) and were further purified from the
3 upper aqueous layer of the TRIzol-chloroform homogenate by Quick-RNA kit (Zymol
4 Research, CA, USA).

5 For RNA sequencing of mice ventricles, it was performed by NovaSeq 150PE platform,
6 generating 20M reads/sample to characterize the transcriptional profile of mice hearts (wild
7 type (WT) versus *Tnnt2*^{R154W} (TT) group, four mice in each group).

8 For RNA sequencing of hiPSCs derived cardiomyocytes treated with or without simvastatin,
9 TruSeq Stranded mRNA sequencing was performed by Phalanx Biotech. In brief, polyA
10 mRNA from an input of 500 ng high quality total RNA (RIN value > 8) was purified,
11 fragmented, and the first- and second-strand cDNA were synthesized. Barcoded linkers were
12 ligated to generate indexed libraries. The libraries were quantified using the Promega
13 QuantiFluor dsDNA System on a Quantus Fluorometer (Promega, Madison, WI). The size
14 and purity of the libraries were analyzed using the High Sensitivity D1000 Screen Tape on an
15 Agilent 2200 TapeStation instrument. The libraries were pooled and run on an Illumina HiSeq
16 2500 sequencer using paired ends 100 bp Rapid Run format to generate 40 million total reads
17 per sample.

18 After sequencing, raw reads were trimmed, removing low quality base, and were used in
19 sequencing by Trimmomatic. The following criteria were applied for raw data cleansing: (1)
20 Cut off when the average quality of sliding window (4-base wide) drops below 15; and (2)
21 Reads shorter than 35 bp were discarded.

22 After the reads were aligned to the genome, Cuffquant was used on the resulting alignment
23 files to compute the gene and transcript expression profiles. Cuffdiff, a part of the Cufflinks

1 package, took the expression profiles and merged assemblies from two or more conditions to
2 estimate the expression levels by calculating the number of RNA-Seq Fragments Per Kilobase
3 of transcript per total Million (FPKM) fragments mapped. Cuffdiff tests the statistical
4 significance of observed changes and identifies genes that are differentially regulated at the
5 transcriptional or post-transcriptional level.

6 Cross-omics data were further analyzed by Perseus software by joining the data of proteome
7 and transcriptome into one Perseus matrix. Both omics columns were sorted and transformed
8 into ranks. A bivariate test was performed on each annotation term. Gene ontology (GO)
9 enrichment analysis was performed to interpret sets of the genes with the functional
10 characterization based on GO system of the classification. The potential interactions between
11 the molecules were predicted by STRING.

12 **11. Chromatin immunoprecipitation sequencing (ChIP-seq) and real-time quantitative chain** 13 **reaction (CHIP-qPCR)**

14 Mice ventricle tissue was cut into small pieces and homogenized in the homogenizer. Nuclei
15 pellets were first extracted with the pre-extraction buffer of nuclear extraction kit (Abcam),
16 then incubated in 0.8% formaldehyde at RT for 15 minutes to cross-link proteins to DNA.
17 Glycine was added to a final concentration of 125 mM glycine to quench the formaldehyde
18 and terminate cross-link reaction. Centrifugation was performed for 5 min, 4°C, 12000rpm,
19 followed by the removal of cross-link buffer, the rinse of nuclei pellet with PBS, and
20 centrifugation again as above. Supernatant was discarded. Pellet was resuspended, re in ChIP
21 lysis buffer (50 mM HEPES-KOH pH7.5, 140 mM NaCl, 1 mM EDTA pH8, 1% Triton X-
22 100, 0.1% Sodium Deoxycholate, 0.1% SDS, Protease Inhibitors), and incubated on ice for
23 15 minutes, then vortexed occasionally. Lysate was transferred to the special vial and sonicate

1 (100% amplitude, on 30 seconds/ off 30 seconds) for 25 minutes to shear DNA to an average
2 fragment size of 200 - 1000 bp. Pallet cell debris was centrifuged for 10 min, 4°C, 8000g.
3 50µl of this chromatin preparation was removed to serve as an input sample, and the remainder
4 will be used for immunoprecipitation. Approximately 10µg of DNA per IP was recommended
5 and each sample was diluted to 500µl with RIPA Buffer. Primary antibodies HDAC1 (1:250,
6 GeneTex), Lamin B1 (1:200, GeneTex), H3K27ac (1:250, GeneTex) and H3K27me3 (1:250)
7 were added to the indicated samples except the beads-only control and the sample was rotated
8 at 4°C for 1 hour. The details of antibodies were listed in supplementary Table 1. Meanwhile,
9 25µl protein A/G beads (Thermo scientific) were used per IP, beads were washed three times
10 in RIPA buffer. RIPA Buffer was aspirated, BSA was added to a final concentration of 0.1
11 µg/µl beads, and RIPA Buffer was added to double the bead volume. The sample was
12 incubated for 30 minutes on rotator at RT. RIPA buffer was used to wash the sample once
13 then it was added to double the bead volume. 50µl of blocked protein A/G bead was added to
14 all samples and IP overnight with rotation at 4°C. The next day, the beads were collected with
15 a magnetic stand and the unbound sample was removed. The following washes were
16 performed, once in low salt wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
17 Tris-HCl pH 8.0, 150 mM NaCl), once in high salt wash buffer (0.1% SDS, 1% Triton X-100,
18 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 500 mM NaCl), once in LiCl wash buffer (0.25 M
19 LiCl, 1% NP-40, 1% Sodium Deoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8.0). After
20 each wash, the beads were collected with a magnetic stand and the supernatant was removed.
21 DNA was eluted by adding 120µl of elution buffer (1% SDS, 100mM NaHCO₃) to the protein
22 A/G beads and vortexed slowly for 15 minutes at 30°C. The beads were collected with a
23 magnetic stand and the supernatant was transferred into a fresh tube. 2µL RNase A (10

1 mg/mL) was added at 37°C for 30 minutes, then 2µL proteinase K (20 mg/mL) was added.
2 The sample was then incubated at 55°C for 1 hour to reverse the crosslink. The eluted DNA
3 fragment was purified with the Quick-DNA universal kit (Zymo Research) and diluted to
4 10ng/µL for DNA sequencing (by Illumina Miniseq) or the relative real-time quantitative
5 chain reaction (by Illumina Eco) by the primers listed in Supplementary Table 2.

6 **12. Absolute quantitative real-time PCR**

7 The difference in the gene expressions of the cardiomyocyte treated with or without
8 simvastatin was confirmed by absolute quantification method with Illumina Eco real-time
9 PCR system. The primers were listed in Supplementary Table 3.

10 **13. Immunoblotting**

11 Mice ventricle tissue was cut into small pieces and homogenized in the homogenizer. Cytosol
12 and nuclei lysates of mice ventricles or hiPSC-CMs were extracted with the nuclear extraction
13 kit (Abcam, Cambridge, UK). Proteins were separated by 10% SDS-PAGE and transferred to
14 a polyvinylidene difluoride (PVDF) membrane. The blot was blocked with 5% BSA and
15 incubated with the indicated primary antibodies (Supplementary Table 1) at 4°C overnight.
16 Then, the corresponding HRP-conjugated secondary antibodies were added (1:10000) at RT
17 for 1 hour. The blot was incubated in SuperSignal West Femto Maximum Sensitivity
18 Substrate (Thermo Scientific, CA, USA) for 5 minutes and exposed to UVP imaging system.

19 **14. Chemicals**

20 Dr. Chung-Ming Sun synthesized statin derivative KM-N1-029, which exhibited a purity
21 exceeding 99% as confirmed by HPLC and NMR analysis. The salt form of the compound
22 was dissolved in either distilled water or DPBS, while the non-salt forms were dissolved in

1 DMSO. The other chemical reagents were purchased from Cayman Chemical (Michigan,
2 USA).

3 **15. Off-label use of simvastatin in the proband**

4 Due to an awareness of the advantageous effects of simvastatin as revealed in the study
5 conducted on cardiomyocytes derived from hiPSCs of the probands *in vitro* and on LVNC
6 mice *in vivo*, the parents have requested an adjunctive therapy involving the off-label use of
7 simvastatin for the proband. Subsequent to obtaining informed consent from her parents and
8 verifying the normal levels of creatine kinase (CK), alanine aminotransferase (ALT), and
9 aspartate aminotransferase (AST), the proband commenced a daily regimen of 5 mg (0.385
10 mg/kg/day) of simvastatin. Echocardiographic assessments and monitoring of plasma enzyme
11 levels are to be conducted at each subsequent follow-up visit (ClinicalTrials.gov:
12 NCT06632834).

13 **16. Statistical method Data availability**

14 A two-tailed paired or unpaired t test was employed to assess differences between two groups,
15 while one-way ANOVA with Dunnett's multiple comparisons test or Tukey's post-hoc test
16 was performed for comparisons involving samples from more than three groups.

17 **17. Data availability**

18 All data and materials used for supporting the findings of the current study are available from the
19 corresponding authors upon reasonable request and with materials transfer agreements (MTAs)
20 for animal models or human cells to any researcher in the aim of reproducing or extending the
21 analysis.

22

23

1 **Results**

2 ***Patient characteristics and genetic information***

3 The pedigree of this LVNC family is shown in Figure 1A. The infant (proband) (IIIb) initially
4 presented with poor perfusion, hepatomegaly, cardiomegaly, and high level of NTproBNP
5 (>3,5000 pg/mL). Echocardiogram performed under inotropic support showed dilated LV (the Z
6 score of LV end-diastolic diameter, 4.7) with impaired LV contractility (LV ejection fraction, 26-
7 30 % under milrinone 0.34 mcg/kg/min support) (Figure 1A). Family screening identified that her
8 father (patient IIa) also had dilated LV and low LV ejection fraction (Figure 1A). Echocardiogram
9 data of the other family members, including her grandfather (Ia), grandmother (Ib), mother (IIb),
10 and sister (IIIa), were normal. Genetic examination of this LVNC family found that the proband
11 and her father had heterozygous missense mutations in TNNT2 (chr1:201333464G>A; p.R141W)
12 and MYPN (chr 10: 68210378 A>T; p.S1296T). Her father received carvedilol, losartan, and
13 aspirin, and his cardiac status remained stationary with LVEF around 47-53%.

14 Besides from heart failure, there were no other extracardiac anomaly noted at presentation
15 and during follow-up. CMR may offer more comprehensive information for myocardial pathology
16 survey and is considered the gold standard for LVNC diagnosis. However, due to the young age
17 and poor CMR resolution at that time, we opted for computed tomography instead of CMR for
18 morphology and LVNC assessment. Computerized tomography in Figure 1B shows normal
19 coronary arteries, dilated LV with hypertrabeculation and non-compaction of the proband (IIIb)
20 heart (The compacted-to-compacted ratios at cardiac apex and lateral wall was 2.2 to 2.4).
21 Myocarditis survey including viral isolation, cardiac enzyme, and ECG study was negative.
22 Dilated cardiomyopathy with LVNC was diagnosed. During the subsequent follow-up, she

1 received medications, including digoxin (3.5-4.5 mcg/kg/d), furosemide (2-3 mg/kg/day),
2 captopril (0.8-1.2 mg/kg/day), carvedilol (0.15-0.3 mg/kg/day), and aspirin (2.5-4 mg/kg/day).
3 About 2 years after the disease onset, her growth was slow, and the body weight was below the
4 3rd percentile. The LV ejection fraction by echocardiography remained poor, ranging from 17.5%
5 to 24.5%. The NTproBNP was between 920 and 1200 pg/mL.

6

7 ***Decrease of cell proliferation in human cardiomyocyte derived from the proband's iPSC***

8 EdU assay was conducted in human cardiomyocytes derived from iPSC of health mother (IIb) and
9 the proband (IIIb) during day 12 to day14 after myogenic differentiation. Cardiomyocytes were
10 identified by antibody against sarcomeric actinin α . Figure 1C shows the prominent decrease of
11 myocyte proliferation in the early differentiated cardiomyocytes of LVNC group.

12

13 ***TNNT2^{R141W} is the pathogenic mutation causing cardiomyopathy***

14 Mice harboring orthologous mutant genes, as identified in the probands, were employed to
15 elucidate the deleterious impacts of the mutations. Distinctive features, such as a thinner non-
16 compact myocardial layer and a thicker trabecular layer, were observed in H&E stained cardiac
17 sections of E15.5 *Tnnt2*^{R154W/+} (T) mouse hearts, in contrast to those in wild type (WT) and
18 *Mypn*^{S1291T/+} (M) mice (Figure 1D). A decrease in myocyte proliferation, as evidenced by a reduced
19 number of myocytes expressing phospho-histone 3 (phospho-S10, PH3), was observed in
20 embryonic E15.5 *Tnnt2*^{R154W/+} (T) mouse hearts in contrast to WT group (Figure 1E). Additionally,
21 Figure 1F, depicting Masson's Trichrome staining, reveals a dilated and thinner myocardium in
22 mice carrying *Tnnt2*^{R154W/+} at 6 weeks of age without significant fibrosis. Assessing cardiac
23 contractile function by echocardiography in mice carrying *Tnnt2*^{R154W/R154W} (TT) or

1 *Mybn*^{S1291T/S1291T} (MM) at 6 weeks of age, Figure 1G demonstrates that mice carrying mutant *Tnnt2*
2 consistently exhibited marked heart failure.

3

4 ***Loss of salt bridge coupling between TNNT2(R141W) and tropomyosin (E-257)***

5 Figure 2A depicts the structure modeling of the protein interaction between troponin T (TnT) and
6 tropomyosin (Tm) by Swiss Model. It highlights the substitution of Try(W) for troponin T Arg(R)-
7 141 resulting in the disruption of the original salt bridge between troponin T (R-141) and
8 tropomyosin (E-257). This structure alteration has impact on the movement of troponin T-
9 tropomyosin during the transformation from calcium free to calcium bound state. As a result, it
10 would potentially impair muscular contraction.

11

12 ***Transcriptomic alteration in the hearts of *Tnnt2*^{R154W/R154W} (TT) mice***

13 In addition to the disruption of a salt bridge between troponin T (W-141) and tropomyosin (E-257)
14 in contribution to cardiac depression, Figure 2B shows that the altered transcriptomic profile of
15 *Tnnt2*^{R154W/R154W} (TT) mice hearts could lead to the pathogenesis of cardiomyopathy. In TT mice
16 hearts, genes related to the negative regulation of TGF- β signaling, sarcomere organization,
17 metabolic pathways, cell polarity, and regulation of the cell cycle were downregulated.
18 Conversely, genes associated with ventricular trabecula myocardium morphogenesis, the TGF- β
19 signaling pathway, and the negative regulation of transcription were upregulated. Volcano plots in
20 Figure 2C illustrate the significant changes in the expression of the genes involved in heart
21 development, ventricular trabecula myocardium morphogenesis, regulation of Notch signaling
22 pathways, and TGF- β signaling pathway. This highlights the additional pathogenic action of
23 mutant TNNT2 in altering cardiac gene expressions.

1 ***Decrease of nuclear TNNT2(R141W)-HDAC1 association***

2 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed to identify the
3 differential TNNT2-interaction-proteins pulldown by the fusion proteins of flag-SBP-
4 TNNT2(WT) and flag-SBP-TNNT2(R141W) expressing in healthy- and LVNC-hCMs transfected
5 with the plasmids of pDEST-TNNT2(WT) and pDEST-TNNT2(R141W) (maps in supplementary
6 figure 3), respectively. It was found a decreased association between TNNT2(R141W) and
7 HDAC1 and an increased association between TNNT2(R141W) and lamin B1 (LMNB1). In
8 nuclear fraction of *Tnnt2*^{R154W/R154W} (TT) mouse hearts, Figure 3A shows that a significant
9 reduction of mutant TNNT2 co-immunoprecipitated with HDAC1 in comparison to those of
10 TNNT2(WT) group, yet the total protein expressions of HDAC1 and mutant TNNT2 were slightly
11 decreased in *Tnnt2*^{R154W/R154W} (TT) mice hearts as shown in Supplementary Figure 4.

12 A proximity ligation assay (PLA) was performed to corroborate the reduced interaction between
13 mutant TNNT2 and HDAC1 in the intranuclear locale of TT mouse cardiomyocytes (Figure 3B),
14 as well as the attenuated association between mutant TNNT2 and HDAC1 in human
15 cardiomyocytes derived from the proband's hiPSC (LVNC-hCM) (Figure 3C), respectively. PLA
16 spot was visualized and spot volume was quantified using Imaris Surfaces, as shown in the right
17 panels of Figure 3B-C. Furthermore, an increased association between mutant TNNT2 and lamin
18 B1 (LMNB1) was observed in LVNC-hCM (Figure 3D), especially the increased volume and
19 number of PLA spots in the perinuclear regions of LVNC-hCM quantified by Imaris Surfaces.

20

21 ***Attenuated intranuclear TNNT2(R141W)-HDAC1 association caused cardiac epigenetic***
22 ***perturbation and the dysregulation of cardiac gene expressions***

1 To further elucidate the differences in chromatin H3K27ac profiling between wild-type (WT) and
2 *Tnnt2*^{R154W/R154W} (TT) mouse hearts, chromatin immunoprecipitation followed by high-throughput
3 sequencing (ChIP-seq) was performed. Figure 4A shows the percentage of the significantly altered
4 H3K27ac profiling in the exons, the gene promoter regions, introns, and the others. There are 458
5 common genes with significant changes in both H3K27ac profiling in the gene promoter regions
6 by ChIPseq and the transcription levels by RNAseq (Figure 4B). The heat map presented in Figure
7 4C illustrates the hierarchical heat map of the genes with significant change in H3K27ac marks
8 within the promoter regions. The top MSigDB gene-sets that significantly enriched (FDR < 0.05)
9 in genes exhibiting decreasing or increasing H3K27ac modifications in *Tnnt2*^{R154W/R154W} (TT) mice
10 hearts are depicted in the upper & lower panel of Figure 4D, respectively. Figure 4E shows a
11 notable decrease in H3K27ac marks within cardiac muscle genes (*Actc1*, *Actn2*, *Lmod2*, *Tnnt2*),
12 Notch signaling genes (*Dll4*, *Hey2*), and chromatin modifier (*Hdac1*) in *Tnnt2*^{R154W/R154W} (TT)
13 mouse hearts. Alternatively, a marked increase was also found in H3K27ac marks within TGFβ
14 signaling genes (*TGFβ1*, *TGFβ2*, *TGFβr1*, *Id3*), Notch signaling genes (*Notch4*, *Hes1*), and
15 chromatin modifier (*Ezh2*) as shown in Figure 4F. It was further found a notable reduction of
16 HDAC1- and LMNB1 (lamin B1)-marks within the promoter region of *Tgfb1* (Supplementary
17 Figure 5) and *Ezh2* (Supplementary Figure 6A). Furthermore, the upregulation of EZH2 in
18 *Tnnt2*^{R154W/R154W} (TT) mice hearts (Supplementary Figure 6B) consequently led to the increase of
19 H3K27me3 marks in *Dll4* promoter region in *Tnnt2*^{R154W/R154W} (TT) mice hearts (Supplementary
20 Figure 6C). Similar finding of the upregulation of EZH2 was validated in LVNC-hCMs
21 (Supplementary Figure 6D). Further study demonstrated that GSK503 (0.3 μM, a selective EZH2
22 inhibitor) can significantly increase *DLL4* expression in LVNC-hCM in Supplementary Figure 6E.
23

1 ***Excessive TGF- β stimulation and reduced Notch activity inhibited LVNC-hCM proliferation***

2 EdU assay was performed to measure the change of LVNC-hCM proliferation *in vitro*. Figure 5A
3 shows the inhibitory effect of TGF- β 1 on cell proliferation of healthy human cardiomyocytes
4 (health-hCM). However, the absence of a discernible inhibitory response to TGF- β 1 on cell
5 proliferation in LVNC-hCM, coupled with a pronounced increase in myocyte proliferation in the
6 presence of A83-01, a TGF- β R1 inhibitor, indicated excessive TGF- β stimulation under basal
7 conditions in LVNC-hCM.

8 In addition, Figure 5B shows that myocyte proliferation can be significantly attenuated by DAPT,
9 a γ -secretase inhibitor, in healthy-hCM but not in LVNC-hCM, implying a reduction of Notch-
10 dependent cell proliferation in LVNC-hCM. This observation was further substantiated by the
11 notable decrease in DLL4⁺ myocytes, rather than JAG1⁺ myocytes in LVNC-hCM as depicted in
12 Figure 5C. The functional validation in Figure 5D underscores the substantial repopulation of
13 DLL4⁺/EdU⁺ LVNC-hCM achieved through treating GSK503 (a EZH2 inhibitor) that can recover
14 DLL4 expression (Supplementary Figure 6E).

15

16 ***Simvastatin can rescue TNNT2(R141W)-HDAC1 association to recover cardiac epigenetic,***
17 ***proteomic profile and function***

18 Statins have previously been documented to possess anticancer properties by modulating cancer
19 epigenetics through their interaction with HDAC^{19,20}. A repurposed drug screen was performed to
20 identify simvastatin being capable of acting as a chemical chaperone, effectively restoring the
21 association between TNNT2(R141W) and HDAC1 in a dose-dependent manner within LVNC-
22 hCM transfected with pDEST-flag-SBP-TNNT2(R141W), as depicted in Figure 6A. The
23 reduction of TNNT2 co-immunoprecipitated with HDAC1 from the nuclear fraction of LVNC-

1 hCM can be substantially reestablished in the presence of simvastatin at 0.1 μ M, as demonstrated
2 in Figure 6B. This is in line with the concurrent attenuation of EZH2 expression in simvastatin-
3 treated LVNC-hCM, as shown in Figure 6C. Furthermore, a dose-dependent effect of simvastatin
4 in the increase of LVNC-hCM proliferation was observed, as presented in Figure 6D. Simvastatin
5 treatment from day 30 through day 70 can also dose-dependently preserve the intracellular calcium
6 handling properties measured by continuously optical pacing at 1Hz in LVNC-hCM expressing
7 GECIs and Chr2-K-GECO, as indicated in Figure 6E.

8 β AR-stimulated positive inotropic effect was prominently blunted in LVNC-hCM *in vitro* (Figure
9 7A). Subsequently, an investigation was carried out to assess whether HDAC inhibitor or other
10 statins could exert a therapeutic effect in recovering the responsiveness to β AR-stimulation in
11 LVNC-hCM *in vitro*. The pan HDAC inhibitor SAHA demonstrated a mild improvement in the β -
12 responsiveness of LVNC-hCM as displayed in Figure 7A. Furthermore, only simvastatin and
13 lovastatin, characterized by the inclusion of the essential structure comprising naphthalene and
14 mevalonolactone (Supplementary Figure 7), exhibited a significant beneficial effect in enhancing
15 β -responsiveness in LVNC-hCMs following treatment from day 30 to 70, as shown in Figure 7A.
16 Statins lacking naphthalene, such as atorvastatin and fluvastatin, or statin derivatives lacking the
17 hydroxy side group on mevalonolactone, such as KM-N1-029, did not manifest any beneficial
18 effects in muscular contraction and β -responsiveness in LVNC-hCMs, as illustrated in Figure 7A.
19 Proteomic study further demonstrated that simvastatin can restore the protein profiles of LVNC-
20 hCMs (iH & iF) approaching to those of health-hCMs (iM & health.m) in terms of promoter
21 activity, cardiac muscle, and metabolism constructed the network by STRING with GOBP (Gene
22 Ontology Biological Process) annotations, as illustrated in Figure 7B.

23

1 ***Therapeutic effect of simvastatin in LVNC mice in vivo***

2 *Tnnt2*^{R154W/+}::*Mypn*^{S1291T/+} mice were utilized to assess the therapeutic potential of simvastatin *in*
3 *vivo*. A prolonged therapeutic regimen was implemented, involving the use of an osmotic pump
4 (ALZET, model 2006, total duration: 6 weeks) for controlled drug delivery to
5 *Tnnt2*^{R154W/+}::*Mypn*^{S1291T/+} mice *in vivo*. The implanted osmotic pump was replaced with a new
6 one every 6 weeks. Continuous treatment with simvastatin (165 nmole/mouse/day) led to a gradual
7 and substantial improvement in left ventricular ejection fraction (LVEF) in
8 *Tnnt2*^{R154W/+}::*Mypn*^{S1291T/+} mice, as observed over a 126-day period (Figure 7C). However, upon
9 discontinuation of the drug after day 84, a relapse in the progression of heart failure was noted.

10

11 ***The therapeutic benefit of off-label use of simvastatin in TNNT2^{R141W/+}-LVNC patient***

12 Due to the evidence of simvastatin-produced beneficial effects in LVNC-hCM *in vitro* and
13 LVNC-mice *in vivo*, the off-label use of simvastatin in add-on manner with the state-of-the-art
14 medications was initiated after having the patient's informed consent. The proband received 5 mg
15 once daily (0.385 mg/Kg/day). No adverse effects were observed. The echocardiography of her
16 cardiac condition in Figure 7D shows (i) LVEF of 21.7% on the time point of two years before
17 simvastatin treatment and (ii) the improved cardiac function to LVEF of 41.1% after the
18 simvastatin therapy for consecutive two years (ClinicalTrials.gov: NCT06632834). Her body
19 weight improved from the 3rd percentile to the 10th percentile. The NTproBNP level was lowered
20 to 182.6 pg/mL in concurrence with the decrease of cardiac size (Z score 3.93) measured by
21 echocardiography. No adverse effects were observed during treatment.

22

1 Discussion

2 Given the documented existence of over 32 distinct genetic mutations associated with Left
3 Ventricular Non-Compaction Cardiomyopathy (LVNC) ²¹, there arises an opportunity for
4 pharmaceutical interventions to selectively target the pathological signaling cascades induced by
5 these mutant genes. From investigating the pathological mechanism of a missense mutation in
6 TNNT2, the present study provided novel insights into the epigenetic regulatory function of
7 intranuclear troponin T (TNNT2) through serving as a sponge of HDAC1 for the maintenance of
8 cardiac epigenetic to facilitating the preservation of cardiac functional gene expressions. In
9 addition, TNNT2(R141W) exhibited a diminished affinity to intranuclear HDAC1 and an
10 enhanced affinity to lamin B1, especially perinuclear distribution, in LVNC myocytes. The
11 redistributed intranuclear HDAC1 resulted in a decrease in H3K27ac marks in specific cardiac
12 genes associated with muscle contraction, calcium handling, and mitochondrial metabolism,
13 consequently leading to gene downregulation and cardiac dysfunction. Alternatively, the decrease
14 of HDAC1 associated with TNNT2(R141W)-lamin B1 complex in perinuclear region may
15 contribute to an increase in H3K27ac marks in the genes involved in TGF β signaling and EZH2.
16 It consequently leads to the inhibition of cardiac growth via TGF β -overstimulation and the
17 attenuated NOTCH activity due to DLL4 downregulation caused by the overexpressed EZH2-
18 mediated increase of H3K27me3 mark in DLL4 promoter region. Through drug repurposing
19 screen in hiPSC-derived cardiomyocytes from affected individuals (LVNC-hCMs) to explore the
20 chemical chaperone for reinstating TNNT2(R141W)-HDAC1 association, simvastatin was
21 identified to exert therapeutic potential capable of improving cardiac function by normalizing
22 cardiac epigenetics and omics profiles. The therapeutic efficacy of simvastatin was demonstrated
23 in both LVNC-hCMs *in vitro* and LVNC mice carrying *Tnnt2*^{R154W} *in vivo*. Continuous simvastatin

1 treatment was found to be necessary to prevent the recurrence of heart failure progression, as
2 evidenced by the *in vivo* LVNC mouse study. This study successfully elucidated the role of
3 intranuclear TNNT2 in cardiac epigenetic homeostasis, the underlying mechanism of
4 TNNT2(R141W) in LVNC pathogenesis, and the potential druggable targets in the signaling
5 cascades.

6 Different mutation sites on *TNNT2* have been associated with various types of
7 cardiomyopathy (CMP). Mutations in *TNNT2* on the sites of I79N²², R92L/R92Q²³/R92W^{24, 25},
8 F110I, R130C²⁴, Delta E160²⁶, E163K²², K263R²⁷, and R278C²⁸ have been reported to be linked
9 to familial hypertrophy cardiomyopathy (HCM). In contrast, mutations including N83H²⁹, L84F³⁰,
10 R141W²², R173W^{22, 31}, R183W³², and DeltaK210³³ have been associated with dilated
11 cardiomyopathy (DCM). However, the precise mechanisms by which different *TNNT2* mutations
12 lead to HCM or DCM, as well as the development of therapeutic medications targeting the
13 pathological signaling pathways caused by these mutations, are not yet fully understood. In the
14 present study, *TNNT2*^{R141W} mutation was identified from an LVNC infant with DCM feature.
15 Prominent hypertrabeculation and left ventricle noncompaction was also observed in the
16 embryonic hearts of the knock-in mice harboring the orthologous *Tnnt2*^{R154W} mutation.
17 *TNNT2*^{R141W} has been reported to be associated with DCM.²² In the present study, DCM features
18 appeared in adult *Tnnt2*^{R154W} mice at the age over 6 weeks (Figure 1F), suggests that LVNC with
19 *TNNT2*^{R141W} mutation can further progress to DCM. This suggests that the phenotypic
20 manifestation of LVNC is intricately determined by distinct genetic mutations within each
21 individual and the timing of disease surveillance. This underscores the vital significance of
22 employing advanced cardiac imaging techniques in pediatric patients to ensure precise diagnosis,
23 thus establishing a solid foundation for the progression of precision medicine in the future.

1 Computer simulations of the protein structure have predicted that the mutant troponin T
2 (TNNT2(R141W)) may lose its functional coupling with tropomyosin due to the disruption of the
3 salt bridge between TNNT2(W-141) and the carboxylate side-chain of tropomyosin (E-257). This
4 molecular alteration could potentially result in muscle weakness, which cannot be rescued by
5 simvastatin. However, manipulating TNNT2(R141W)-mediated pathological signaling should be
6 promising to control disease progression. Prior studies have suggested the nuclear localization of
7 TNNT2 in cardiomyocytes.^{31, 34} In TNNT2(R173W)-induced dilated cardiomyopathy (DCM), it
8 is proposed that an increased interaction of nuclear TNNT2(R173W) with KDM1A (LSD1) and
9 KDM5A (JARID1) might induce cardiac epigenetic modifications by redistributing these histone
10 demethylases, thereby increasing H3K4me3 marks in the regions of PDE2A. These modifications
11 in turn could lead to an abnormal upregulation of phosphodiesterase (PDE2A) and contribute to
12 the loss of β -AR responsiveness in DCM.³¹ The current study further investigated the involvement
13 of nuclear TNNT2 in the formation of the TNNT2-HDAC1 complex (Figure 3). This complex is
14 suggested to serve as an HDAC1 sponge, regulating the intranuclear distribution of HDAC1 and
15 maintaining the euchromatin structure of functional cardiac genes, thereby facilitating cardiac gene
16 expressions. Notably, the mutant TNNT2(R141W) exhibited a diminished interaction with
17 intranuclear HDAC1 while displaying an increased association with lamin B1 in the perinuclear
18 region. Consequently, the redistribution of HDAC1 from intranuclear TNNT2(R141W) may
19 contribute to the formation of a heterochromatin structure in cardiac genes responsible for
20 encoding functional proteins involved in muscle contraction and heart development (Figure 4D-
21 F). Conversely, an enhanced euchromatin state may be observed in genes related to TGF β
22 signaling molecules and EZH2. Notably, early differentiated LVNC-hCMs displayed excessive
23 TGF β activity, which inhibited myocyte proliferation (Figure 5A), leading to cardiac growth

1 impairment (Figure 1). Additionally, the aberrant upregulation of EZH2 induced by
2 TNNT2(R141W) also contributed to a defect in cardiac growth. This defect arises from the
3 reduction of Notch-dependent stimulation in myocyte proliferation, occurring through the
4 inhibition of DLL4 expression via epigenetic modifications. Previous reports have documented
5 the overexpression of EZH2 in ischemic cardiomyopathy³⁵ and dilated cardiomyopathy.³⁶ EZH2,
6 as an enzymatic component of the polycomb repressive complex 2 (PRC2) belonging to the SET
7 domain family of histone-lysine N-methyltransferases, facilitates the trimethylation of lysine-27
8 on histone H3 (H3K27me3), thereby promoting heterochromatin formation and transcriptional
9 repression.³⁷ The observed increase in H3K27me3 marks and decrease in H3K27ac marks in the
10 *DLL4* gene correspond to the aberrant upregulation of *EZH2* and the downregulation of *DLL4* in
11 LVNC-hCM. Functional validation demonstrated that the direct inhibition of EZH2 significantly
12 enhances DLL4 expression in LVNC-hCM, ultimately leading to improved myocyte proliferation
13 (Figure 5D).

14 The schematic diagram I illustrates the druggable targets that have been identified in the
15 pathological signaling cascade mediated by TNNT2(R141W). Given the reduced interaction of
16 nuclear TNNT2(R141W) with HDAC1, resulting in an epigenetic perturbation caused by the
17 redistributed HDAC1, one noteworthy target emerges as HDAC1. It has been reported that HDAC
18 inhibition may improve cardiac diastolic dysfunction^{38, 39}. Notably, our study found SAHA, a pan
19 HDAC inhibitor, exhibits promise in partially restoring β -AR responsiveness by rectifying
20 heterochromatin patterns in cardiac functional genes that have been impacted by the redistributed
21 HDAC. However, the increased TNNT2(R141W)-laminB1 association concomitantly with the
22 diminished TNNT2(R141W)-HDAC1 association within the perinuclear region leads to
23 anomalous euchromatin configurations in genes such as TGF β -signaling molecules and EZH2.

1 HDAC inhibitors might worsen this pathological signaling. Thus, the utilization of a TGF β R1
2 inhibitor (A83-01) appears to counteract TGF β -mediated inhibitory influences on cell
3 proliferation, thereby enhancing LVNC myocyte proliferation, as visually depicted in Figure 5A.
4 Within the context of restoring DLL4 expression, employing an EZH2 inhibitor (GSK503) has
5 demonstrated a significant propensity to increase LVNC-hCM proliferation. Although these
6 approaches can improve cardiac growth, they cannot prevent heart failure progression caused by
7 TNNT2(R141W)-induced HDAC redistribution. An ideal pharmacological strategy for
8 comprehensively obstructing TNNT2(R141W)-mediated pathological pathways entails the
9 restoration of interaction between TNNT2(R141W) and HDAC1. Simvastatin, a hit repurposed
10 drug derived synthetically from a fermentation product of *Aspergillus terreus*, can reestablish the
11 TNNT2(R141W)-HDAC1 association and significantly improve cardiac function among statins.
12 The potential direct interaction between statins and HDAC2 was reported by computation
13 modeling²⁰. The present study further demonstrated that only simvastatin and lovastatin, rather
14 than the other statins shown in supplementary Figure 7, can act as a chemical chaperone to improve
15 cardiac growth and function of LVNC-hCMs *in vitro* and *Tnnt2*^{R154W/+::Mybn}^{S1291T/+} mice *in vivo*
16 through reinstating the association of TNNT2(R141W) and HDAC1. Although the dosage range
17 and specific indications remain unclear, our study shows the optimal dose of simvastatin, 165
18 nmol/mouse/day, via subcutaneous-osmotic-pump-administration can significantly produce
19 functional improvement in *Tnnt2*^{R154W} mice *in vivo* (Figure 7C).

20 Simvastatin has been used in children with various underlying diseases, including a history
21 of organ transplantation, renal disease, and familial hypercholesterolemia^{40, 41, 42}. No significant
22 safety concerns have been identified. Because of the beneficial effects of simvastatin from the
23 study in cardiomyocytes derived from the probands' hiPSCs *in vitro* and in LVNC mice *in vivo*,

1 an add-on therapy with off-label use of simvastatin in the proband was initiated after obtaining her
2 parents' agreement. The baseline of the proband's cardiac condition during 30 months after the
3 disease onset shows the poor prognosis of the proband's cardiac function (LVEF 20-30 %)
4 measured by echocardiography and NTproBNP level above 900 pg/mL. The proband began to
5 receive 5 mg (0.385 mg/Kg/day) once daily (ClinicalTrials.gov: NCT06632834). After the
6 simvastatin therapy for consecutive 2 years, cardiac function was significantly improved to be
7 LVEF above 41.1%. Her body weight improved from the 3rd percentile to the 10th percentile. The
8 NTproBNP level was lowered to 182.6 pg/mL in association with the decrease of cardiac size (Z
9 score 3.93). No adverse effects were observed during the treatment.

10 These observations highlight the potential for epigenetic modulation as a therapeutic strategy for
11 LVNC and underscore the importance of further investigations to elucidate the underlying
12 mechanisms driven by different TNNT2-mutations mediated epigenetic dysregulation. Ultimately,
13 a better understanding of these processes may contribute to the development of innovative
14 therapeutic approaches for patients with LVNC. This preclinical trial in a dish *in vitro* and
15 functional validation in LVNC mice *in vivo* provide a warrant of success for the future clinical
16 trial.

17

18

19

20

21

22

1 **Acknowledgments:**

2 We thank the grant support provided by National Science and Technology Council in Taiwan
3 (NSTC), National Health Research Institutes (NHRI), and the Excellent Translational Medicine
4 Research Projects of National Taiwan University College of Medicine and National Taiwan
5 University Hospital (ETMRP).

6 NSTC105-2320-B-002 -036 -MY3, NSTC106-2314-B-002-207, NSTC108-2320-B-002 -027 -
7 MY3, NHRI-EX112-11141SI, ETMRP-106R39012 & -1105F025-02 to C.W.P.


8 NSTC106-2314-B-002-207 & NSTC109-2314-B-002-140 to W.M.H.

9 NSTC-105-2314-B-002 -109 -MY3, NSTC107-2319-B-001 -003, ETMRP-106R39012 and
10 ETMRP-1105F025-02 to H.H.N.

11 We would like to acknowledge the service provided by Hua-Man Hsu & Shao-Chun Hsu at the
12 imaging core facility of the First Core Laboratory, and Hsueh-Chin Chen & Wei-Jou Lin at
13 Laboratory Animal Center, National Taiwan University College of Medicine. We thank the
14 technical services provided by Suz-Ying Chen in the maintenance of hiPSC, the technical service
15 for the generation of gene-targeting knock-in mice by the Transgenic Mouse Model Core Facility
16 of the National Core Facility Program for Biotechnology, Ministry of Science and Technology,
17 Taiwan and the Gene Knockout Mouse Core Laboratory of National Taiwan University Center of
18 Genomic Medicine, Transmission Electron Microscopy (TEM) service by Dr. Hsiuni Kung at
19 Graduate Institute of Anatomy and Cell Biology & Mr. Yansheng Wu at College of Medicine, Fu
20 Jen Catholic University, and ChIPseq by Chia-Lang Hsu at Department of Medical Research in
21 NTUH. We thank the staff of the Sequencing Core and the High-throughput Genomics and Big
22 Data Analysis Core, Department of Medical Research, National Taiwan University Hospital for
23 technical support. We thank the English editing by Sen-Han Chang

1 **Figures & figure legends**


Figure 1



2
3 **Figure 1. Characterization of disease phenotype in a LVNC family and mice harboring**
4 **patients' mutant genes.** (A) Pedigree of LVNC family carrying $TNNT2^{R141W/+}$ and $MYPN^{S1296T/+}$
5 mutations. Representative acquired echocardiography images of LVNC patients (IIa & IIIb) in
6 right panel were measured from the proband (IIIb, EF=26 %) and her father (IIa, EF=53.1 %). (B)
7 The images of computed tomography (CT) reconstituted coronary arteries and the representative
8 cardiac CT sections of the proband. The arrows indicate the representative LVNC features of
9 hypertrabeculation and non-compaction. (C) The decrease of cell proliferation in human
10 cardiomyocytes derived from the probands' iPSC. Data are mean \pm SEM (n=10). *P<0.05, vs.
11 health group by unpaired t test. (D) The decrease of the thickness in compacted myocardium and
12 the increase of the length in intraventricular trabecula layer in E15.5 embryonic heart of
13 $Tnnt2^{R154W/+}$ (T) mice in comparison to those in wild type (WT) and $Mypn^{S1291T/+}$ (M) mice. Data
14 are mean \pm SEM (n=3). *P<0.05, vs. WT by one-way ANOVA with post-hoc Dunnett's multiple
15 comparison test. (E) A decrease of phospho-histone 3 (PH3) expression in myocytes of E15.5
16 mice carrying $Tnnt2^{R154W/+}$ (n=8) as compared to those in WT group (n=9). Data are mean \pm SEM.
17 *P<0.05, vs. WT group by unpaired t test. (F) Cardiac structure and fibrosis were examined by
18 Masson's trichrome stain in the hearts of WT and mutant ($Tnnt2^{R154W/R154W}$ (TT) &
19 $Mypn^{S1291T/S1291T}$ (MM)) mice at the age of 8-9 weeks old. The scale bar represents 2 mm. (G)
20 Comparison of left ventricular ejection fraction (LVEF) measured by echocardiography between
21 WT and mutant groups of $Mypn^{S1291T/S1291T}$ (MM), $Tnnt2^{R154W/R154W}$ (TT), and
22 $Mypn^{S1291T/+}::Tnnt2^{R154W/+}$ (T::M) at the age of 6 weeks old. Mice carrying $Tnnt2^{R154W}$ exhibited

1 a significant reduction on LVEF. The data represent the mean± SEM (n=10 in each group).
 2 Statistical significance is denoted as *P<0.05, compared to WT, determined using one-way
 3 ANOVA with post-hoc Tukey's test.
 4


Figure 2



5
 6 **Figure 2. Mutant troponin T dose not only cause contractile dysfunction due to the loss of**
 7 **salt bridge between TNNT2(W141) and tropomyosin (E257) but also a significant**
 8 **transcriptomic alteration in *Tnnt2*^{R154W/R154W} mice hearts.** (A) Close-up of residue R141 of
 9 TNNT2 (TnT) highlighting the rearrangement of the nearby electrostatic network in the absence
 10 (a) and presence (b) of Ca²⁺. The structures of human cardiac muscle thin filament in the absence
 11 and presence of Ca²⁺ have been determined by electron cryomicroscopy (PDB codes: 6KN7 and
 12 6KN8). The guanidinium side-chain of TnT R-141 forms a salt bridge with the carboxylate side-
 13 chain of E-257 from tropomyosin (Tm) in the absence and presence of Ca²⁺. Substitution of Trp
 14 for Arg introduces a bulky aromatic side chain and disrupts polar contacts (hydrogen bonds or salt
 15 bridges). (B) RNA sequencing identified the statistically significant differential genes between the
 16 WT versus TT groups by unpaired t-tests. Hierarchical clustering heat maps were generated
 17 utilizing the Euclidean distance method to measure dissimilarities between sample pairs for each
 18 gene across all samples. The scale bar of Z-score was provided on the right side of the heatmap.
 19 Bubble plots were employed to visualize the biological functions or pathways associated with the
 20 differential genes of either higher level in WT or in TT, utilizing GOBP (circle), GOMF (triangle).
 21 GOCC (hexagon) and KEGG (square). The size of the symbols indicates the count number of the
 22 genes involved, while the color represents fold enrichment. (C) Volcano plots were utilized to

1 depict the fold change of differential genes associated with specific KEGG pathways in
 2 comparison between WT and TT groups.
 3
 4


Figure 3



5
 6 **Figure 3. Mutant troponin T decreased the association with nuclear HDAC1 but increased**
 7 **the association with perinuclear LMNB1 (LAMIN B1) in LVNC cardiomyocytes.** (A) The
 8 decrease of TNNT2 co-IP with HDAC1 from the nuclear fractions of *Tnnt2*^{R154W/R154W} (TT) mice
 9 hearts in comparison to that of wild type (WT) group. The level of co-IP TNNT2 was normalized
 10 to that of IP-HDAC1 in each sample. Data are mean±SEM (n=5). *P<0.05, versus WT group, by
 11 unpaired t test. Proximity ligation assay (PLA) was employed to identify the colocalized spots of
 12 TNNT2 & HDAC1 (red PLA spot: troponin T (TnT)+HDAC1; blue: DAPI) in the nuclei of (B)
 13 WT & TT mice ventricular cardiomyocytes and (C) Health-hCM & LVNC-hCM. The lower panels
 14 under cytofluorescence images show the contour of PLA spots (pink) in myocyte nuclei (purple)
 15 illustrated by Imaris surface software. The volume of PLA spot was quantified by Imaris surface.
 16 The scatter plot of PLA spot volume was illustrated in the right panel. Data are mean±SEM (n=3,
 17 three different samples in each group). *P<0.05, versus WT or health group, by unpaired t test.
 18 (D) Comparison of the volume and the perinuclear distribution of PLA spot constructed by
 19 antibodies targeting TNNT2 and LMNB1 (red PLA spot: troponin T (TnT)+ lamin B1; blue:
 20 DAPI) in Health- and LVNC-hCMs via the image analysis by Imaris surface. TNNT2-lamin B1
 21 (LMNB1) complex distributed within the border of nuclei DAPI was illustrated as the pink
 22 perinuclear PLA spots. The scatter plot of the perinuclear PLA spot volume was illustrated in the
 23 right panel. Data are mean±SEM (n=3, three different batches of hCMs in each group). *P<0.05,
 24 versus health group, by unpaired t test.

25

Figure 4




1
2 **Figure 4. Mutant troponin T altered H3K27ac marks in cardiac genes involving in heart**
3 **development and cardiac muscle contraction. (A) The percentage of H3K27ac marks in the**

1 different chromosome regions examined by ChIPseq. (B) There are 458 genes that exhibit
2 consistent change in both H3K27ac marks in the gene regions and the transcriptional expressions.
3 (C) Hierarchical clustering heatmap of mice genes exhibiting significant change in gene regions
4 where H3K27Ac marks were identified by ChIP-seq in the hearts of wild type (WT) and *Tnnt2*^{R154W}
5 (TT) mice (three different mice hearts in each group). (D) The bubble plots reveal the top enriched
6 MSigDB gene-sets of 458 genes with significant decrease (upper panel) and unique increase (lower
7 panel) of H3K27ac modification in gene regions of TT group. (E-F) ChIP-seq tracks for H3K27ac
8 at the regions of representative genes with loss of H3K27ac marks (*Actc2*, *Actn2*, *Lmod2*, *Tnnt2*,
9 *Dll4*, *Hey2*, *Hdac1*) and gain of H3K27ac (*Tgfβ1*, *Tgfβ2*, *Tgfβr1*, *Id3*, *Notch4*, *Hes1*, *Ezh2*) in TT
10 group (red track) in comparison to those in WT group (blue track). All data were normalized to
11 the corresponding input of each sample. The representative trace was summed from three
12 independent samples in each group. Chromosomal loci & reference sequence of these genes was
13 shown in the top & bottom panels, respectively.


14
15
16
17
18
19
20
21
22
23
24
25

Figure 5



1
2
3 **Figure 5. The excessive TGFβ stimulation and the reduced NOTCH activity in LVNC-hCM**
4 **caused cardiac growth defect.** Pulse-chase EdU assay with Alexa Fluor 647 fluorescent label
5 was performed to examine cell proliferation of hiPSC-derived cells with the indicated drug
6 treatment during day 12 through day 16 after myogenic differentiation. Human cardiomyocytes
7 were identified by mouse monoclonal antibody targeting sarcomeric actinin α (SA, with anti-
8 mouse IgG secondary antibody conjugated with Alexa Fluor 488). Flowcytometry was performed
9 to quantify the cell population by BD LSRFortessa. (A) The proliferation rate of LVNC-hCM was
10 lower than that of Health-hCM. TGFβ1 (3 nM) can prominently decrease EdU+ myocytes in
11 health-hCM but not those in LVNC-hCM. A83-01 (3 μM), a TGFβR1 inhibitor, can markedly
12 increase EdU+ myocytes in LVNC-hCM. Data are mean±SEM (n=3 in each group). *P<0.05,
13 versus control or the indicated groups by one-way ANOVA with post-hoc Tukey's test. (B) The
14 difference of EdU+/SA+ myocyte population between control and DAPT (0.3 μM)-treated groups
15 was defined as the capacity of Notch-dependent myocyte proliferation that was significantly
16 decreased in LVNC-hCM. Data are mean±SEM (n=3 in each group). *P<0.05, versus control by
17 one-way ANOVA with post-hoc Tukey's test. (C) DLL4+ myocytes were decreased in LVNC-
18 hCM and could be further depleted by DAPT (0.3 μM). The lower panel shows the cell population
19 percentage averaged from three independent samples (n=3 in each group). (D) The cell population
20 of DLL4+/EdU+ LVNC-hCM (in red square) can be increased by GSK (0.3 μM). Data are
21 mean±SEM (n=4 in each group). *P<0.05, versus control by unpaired t test.

Figure 6




1
 2 **Figure 6. Simvastatin can restore the association between TNNT2(R141W) and HDAC1 to**
 3 **improve cardiac growth and function of LVNC-hCM.** (A) TNNT2(R141W)-associated
 4 proteins were pulled down by streptavidin-beads from nuclear fraction of LVNC-hCM transfected
 5 with pDEST-TNNT2(R141W) encoding the fusion protein of flag-SBP-TNNT2(R141W) in the
 6 absence or presence of simvastatin at the concentrations of 0.1 and 0.5 μ M. Simvastatin can dose-
 7 dependently increase the associated TNNT2(R141W)-HDAC1 complex. Data are mean \pm SEM
 8 (n=4 in each group). *P<0.05, versus control by one-way ANOVA with post-hoc Tukey's test.
 9 (B) Co-immunoprecipitation of HDAC1 and TNNT2 from nuclear fraction of LVNC-hCM treated
 10 with or without simvastatin (0.1 μ M). A significant increase of TNNT2 co-immunoprecipitated by
 11 HDAC1 was observed in simvastatin-treated LVNC-hCM. Data are mean \pm SEM (n=3-5 in each
 12 group). *P<0.05, versus LVNC by one-way ANOVA with post-hoc test by Dunnett's multiple
 13 comparisons test. (C) The upregulation of EZH2 in LVNC-hCM was prominently abolished by
 14 simvastatin (0.1 μ M). Data are mean \pm SEM (n=4 in each group). *P<0.05, versus LVNC without
 15 simvastatin treatment by one-way ANOVA with post-hoc Tukey's test. (D) Click-it EdU assay
 16 with Alexa Fluor 647 fluorescent label was performed to examine the proliferation of myocytes
 17 identified by mouse monoclonal antibody targeting sarcomeric actinin α with secondary antibody
 18 conjugated with Alexa Fluor 488. Simvastatin can dose-dependently increase pulse-chase-labeled
 19 EdU+ LVNC-hCM during day 12-16 after myogenic differentiation at the concentrations ranging
 20 from 0.1, 0.5 and 1 μ M. Data are mean \pm SEM (n=3 in each group). *P<0.05, versus control by one-
 21 way ANOVA with post-hoc Tukey's test. (E) LVNC-hCMs expressing K-GECO (a genetically
 22 encoded calcium indicator) and channelrhodopsin-2 delivered by AAV were used to measure

1 intracellular calcium transients elicited by optical pacing at 1 Hz (indicated by blue lines).
2 Intracellular calcium transients were measured every week. A marked decrease in the amplitude
3 of calcium transients of LVNC-hCMs was observed from day 50 through 70. The representative
4 traces in left panel show a significant increase of calcium transients in simvastatin (S)-treated
5 group at the concentrations of 0.1, 0.5, and 1 μ M in LVNC-hCM from day 30 through day 70 after
6 myogenic differentiation. Data are mean \pm SEM (n=10 different LVNC-hCMs in control, n=22
7 different LVNC-hCMs in S group). *P<0.05, versus control at the same time point by unpaired t
8 test.

9
10
11
12
13
14
15
16
17
18
19
20
21

Figure 7



1

2 **Figure 7. Functional improvement of LVNC cardiomyocytes *in vitro* and hearts *in vivo* by**

3 **simvastatin.** (A) The structure and activity relationship between simvastatin & its analogs was

4 established through measuring myocyte shortening velocity ($V_{\text{shortening}}$) in response to isoprenaline

5 (at the concentrations of 0.03, 0.3 and 1 μM) in LVNC-hCMs treated with the indicated reagents

6 (1: control, 2: SAHA (200 nM), 3: Atorvastatin (300 nM), 4: Fluvastatin (300 nM), 5: Simvastatin

7 (300 nM), 6: Lovastatin (300 nM) and 7: KM-N1-029 (300 nM). Health-hCM was used as normal

8 control in response to β -stimulation. (B) Heatmap and PCA of proteomic profile of health-hCM

9 (iM & Health,m)- and LVNC-hCM (iFa & iH) on day 70 after the treatment with vehicle (ctrl:

10 control) or with simvastatin (S, 0.1 μM) from day 30 through day 70. The functional protein

11 association network of simvastatin-recovered proteins expressing in both of iFa & iH LVNC-

12 hCMs within the clusters of GOBP annotations including muscle contraction, glucose metabolism

13 and promoter activity was constructed using STRING. The green arrows indicate the shift direction

14 of the proteomic profile in two LVNC-hCM lines with simvastatin-treatment. (C) LVEF of

15 $\text{Tnnt2}^{\text{R154W/+}}::\text{Mypn}^{\text{S1291T/+}}$ mice could be prominently improved in continuous simvastatin

16 treatment via osmotic pump (165 nmole/mouse/day) for consecutive 126 days. Severe heart failure

17 was relapsed on day 126 once withdrawal simvastatin from day 84. Data are mean \pm SEM (n=6 in

18 each group). *P<0.05, versus LVEF before treatment (day 0) by paired t test. (D) The change of


19 LVEF (circle) and plasma NTproBNP (square) of this proband before and after simvastatin (5 mg

20 per day, p.o.) treatment. The upper panel is the representative pictures of echocardiography at the

1 time points of (i) two years before simvastatin treatment and (ii) two years after consecutive
 2 treatment with simvastatin.

3
 4
 5
 6

Schematic diagram I



7
 8
 9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30

Schematic diagram. TNNT2(R141W)-mediated pathological signaling pathways and druggable targets. (A) Troponin T (TNNT2) can act as an HDAC1 sponge in the nuclei of healthy cardiomyocytes to maintain cardiac epigenetic and gene expressions. In contrast, a weakened association between mutant troponin T (TNNT2(R141W)) and HDAC1 within the nuclei of LVNC-cardiomyocytes could lead to the redistribution of nuclear HDAC1 to perturbate cardiac epigenetic. The decline in H3K27Ac marks within cardiac genes encoding the proteins functioning in muscle contraction and metabolism coincided with the downregulation of these affected genes and cardiac dysfunction. Concurrently, the increase in H3K27Ac marks within the promoter regions of TGF-β signaling molecules and EZH2 aligned with an abnormal upsurge in TGF-β stimulation and EZH2 upregulation. The increased EZH2 caused the downregulation of DLL4 expression. The excessive TGF-β stimulation and the diminished Notch DLL4 activity contribute to the decrease of myocyte proliferation and cardiac growth defect. (B) The administration of EZH2 inhibitor and TGF-βR1 inhibitor exhibited improvements in cardiac growth, while the use of an HDAC inhibitor partially ameliorated cardiac βAR responsiveness via inhibiting the redistributed HDAC1 to recover cardiac gene expression. Simvastatin demonstrated comprehensive improvement of cardiac growth and function through the restoration of the intranuclear TNNT2(R141W)-HDAC1 association.

1 References:

- 2
- 3 1. Towbin JA, Lorts A, Jefferies JL. Left ventricular non-compaction cardiomyopathy. *Lancet* **386**, 813-825
4 (2015).
- 5
- 6 2. Finsterer J, Stollberger C, Towbin JA. Left ventricular noncompaction cardiomyopathy: cardiac,
7 neuromuscular, and genetic factors. *Nat Rev Cardiol* **14**, 224-237 (2017).
- 8
- 9 3. Shi WY, *et al.* Long-Term Outcomes of Childhood Left Ventricular Non-Compaction Cardiomyopathy:
10 Results from a National Population-Based Study. *Circulation*, (2018).
- 11
- 12 4. Luxán G, *et al.* Mutations in the NOTCH pathway regulator MIB1 cause left ventricular noncompaction
13 cardiomyopathy. *Nat Med* **19**, 193-201 (2013).
- 14
- 15 5. Zhang W, *et al.* Tbx20 transcription factor is a downstream mediator for bone morphogenetic protein-10 in
16 regulating cardiac ventricular wall development and function. *J Biol Chem* **286**, 36820-36829 (2011).
- 17
- 18 6. Pignatelli RH, *et al.* Clinical characterization of left ventricular noncompaction in children: a relatively
19 common form of cardiomyopathy. *Circulation* **108**, 2672-2678 (2003).
- 20
- 21 7. Sedaghat-Hamedani F, *et al.* Clinical genetics and outcome of left ventricular non-compaction
22 cardiomyopathy. *Eur Heart J* **38**, 3449-3460 (2017).
- 23
- 24 8. Zhao C, *et al.* Numb family proteins are essential for cardiac morphogenesis and progenitor differentiation.
25 *Development* **141**, 281-295 (2014).
- 26
- 27 9. Digilio MC, *et al.* Syndromic non-compaction of the left ventricle: associated chromosomal anomalies.
28 *Clin Genet* **84**, 362-367 (2013).
- 29
- 30 10. Probst S, *et al.* Sarcomere gene mutations in isolated left ventricular noncompaction cardiomyopathy do
31 not predict clinical phenotype. *Circ Cardiovasc Genet* **4**, 367-374 (2011).
- 32
- 33 11. D'Amato G, *et al.* Sequential Notch activation regulates ventricular chamber development. *Nat Cell Biol*
34 **18**, 7-20 (2016).
- 35
- 36 12. Kodo K, *et al.* iPSC-derived cardiomyocytes reveal abnormal TGF-beta signalling in left ventricular non-
37 compaction cardiomyopathy. *Nat Cell Biol* **18**, 1031-1042 (2016).
- 38
- 39 13. Tavares de Melo MD, *et al.* Decreased glycolytic metabolism in non-compaction cardiomyopathy by 18F-
40 fluoro-2-deoxyglucose positron emission tomography: new insights into pathophysiological mechanisms
41 and clinical implications. *Eur Heart J Cardiovasc Imaging* **18**, 915-921 (2017).
- 42
- 43 14. Bogle C, *et al.* Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the
44 American Heart Association. *Circulation*, (2023).
- 45
- 46 15. Chimenti C, *et al.* A proposed strategy for anticoagulation therapy in noncompaction cardiomyopathy. *ESC*
47 *Heart Fail* **9**, 241-250 (2022).
- 48
- 49 16. Arbelo E, *et al.* 2023 ESC Guidelines for the management of cardiomyopathies. *Eur Heart J* **44**, 3503-3626
50 (2023).
- 51
- 52 17. Bhattacharya S, *et al.* High efficiency differentiation of human pluripotent stem cells to cardiomyocytes
53 and characterization by flow cytometry. *J Vis Exp*, 52010 (2014).
- 54
- 55 18. Chang YF, *et al.* High-Throughput Optical Controlling and Recording Calcium Signal in iPSC-Derived

- 1 Cardiomyocytes for Toxicity Testing and Phenotypic Drug Screening. *J Vis Exp*, (2022).
2
- 3 19. Kodach LL, *et al.* Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic
4 reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway.
5 *Gut* **60**, 1544-1553 (2011).
6
- 7 20. Lin YC, Lin JH, Chou CW, Chang YF, Yeh SH, Chen CC. Statins increase p21 through inhibition of histone
8 deacetylase activity and release of promoter-associated HDAC1/2. *Cancer Res* **68**, 2375-2383 (2008).
9
- 10 21. Rojanasopondist P, Nesheiwat L, Piombo S, Porter GA, Jr., Ren M, Phoon CKL. Genetic Basis of Left
11 Ventricular Noncompaction. *Circ Genom Precis Med* **15**, e003517 (2022).
12
- 13 22. Sommese RF, Nag S, Sutton S, Miller SM, Spudich JA, Ruppel KM. Effects of troponin T cardiomyopathy
14 mutations on the calcium sensitivity of the regulated thin filament and the actomyosin cross-bridge kinetics
15 of human beta-cardiac myosin. *PLoS One* **8**, e83403 (2013).
16
- 17 23. Ford SJ, Mamidi R, Jimenez J, Tardiff JC, Chandra M. Effects of R92 mutations in mouse cardiac troponin
18 T are influenced by changes in myosin heavy chain isoform. *J Mol Cell Cardiol* **53**, 542-551 (2012).
19
- 20 24. Fujita E, Nakanishi T, Nishizawa T, Hagiwara N, Matsuoka R. Mutations in the cardiac troponin T gene
21 show various prognoses in Japanese patients with hypertrophic cardiomyopathy. *Heart Vessels* **28**, 785-794
22 (2013).
23
- 24 25. Vakrou S, *et al.* Differences in molecular phenotype in mouse and human hypertrophic cardiomyopathy. *Sci*
25 *Rep* **11**, 13163 (2021).
26
- 27 26. Kondo T, *et al.* Human-Induced Pluripotent Stem Cell-Derived Cardiomyocyte Model for TNNT2
28 Delta160E-Induced Cardiomyopathy. *Circ Genom Precis Med* **15**, e003522 (2022).
29
- 30 27. Mori AA, *et al.* Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related
31 risk factors in Brazilian patients with hypertrophic cardiomyopathy. *Forensic Sci Int Genet* **52**, 102478
32 (2021).
33
- 34 28. Brunet NM, Chase PB, Mihajlovic G, Schoffstall B. Ca(2+)-regulatory function of the inhibitory peptide
35 region of cardiac troponin I is aided by the C-terminus of cardiac troponin T: Effects of familial
36 hypertrophic cardiomyopathy mutations cTnI R145G and cTnT R278C, alone and in combination, on
37 filament sliding. *Arch Biochem Biophys* **552-553**, 11-20 (2014).
38
- 39 29. Petropoulou E, *et al.* Digenic inheritance of mutations in the cardiac troponin (TNNT2) and cardiac beta
40 myosin heavy chain (MYH7) as the cause of severe dilated cardiomyopathy. *Eur J Med Genet* **60**, 485-488
41 (2017).
42
- 43 30. Li X, *et al.* Cardiac troponin T (TNNT2) mutations in chinese dilated cardiomyopathy patients. *Biomed Res*
44 *Int* **2014**, 907360 (2014).
45
- 46 31. Wu H, *et al.* Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised beta-
47 Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy. *Cell Stem Cell* **17**, 89-100 (2015).
48
- 49 32. Perea-Gil I, *et al.* Serine biosynthesis as a novel therapeutic target for dilated cardiomyopathy. *Eur Heart J*
50 **43**, 3477-3489 (2022).
51
- 52 33. Li B, *et al.* Cardiac Overexpression of XIN Prevents Dilated Cardiomyopathy Caused by TNNT2
53 DeltaK210 Mutation. *Front Cell Dev Biol* **9**, 691749 (2021).
54
- 55 34. Bergmann O, Zdunek S, Alkass K, Druid H, Bernard S, Frisén J. Identification of cardiomyocyte nuclei and
56 assessment of ploidy for the analysis of cell turnover. *Experimental cell research* **317**, 188-194 (2011).

- 1
- 2 35. Pepin ME, *et al.* Genome-wide DNA methylation encodes cardiac transcriptional reprogramming in human
- 3 ischemic heart failure. *Lab Invest*, (2018).
- 4
- 5 36. Tschirner A, Palus S, Hetzer R, Meyer R, Anker SD, Springer J. Six1 is down-regulated in end-stage human
- 6 dilated cardiomyopathy independently of Ezh2. *ESC Heart Fail* **1**, 154-159 (2014).
- 7
- 8 37. Vire E, *et al.* The Polycomb group protein EZH2 directly controls DNA methylation. *Nature* **439**, 871-874
- 9 (2006).
- 10
- 11 38. Travers JG, *et al.* HDAC Inhibition Reverses Preexisting Diastolic Dysfunction and Blocks Covert
- 12 Extracellular Matrix Remodeling. *Circulation* **143**, 1874-1890 (2021).
- 13
- 14 39. Wallner M, *et al.* HDAC inhibition improves cardiopulmonary function in a feline model of diastolic
- 15 dysfunction. *Sci Transl Med* **12**, (2020).
- 16
- 17 40. Lamaida N, Capuano E, Pinto L, Capuano E, Capuano R, Capuano V. The safety of statins in children. *Acta*
- 18 *paediatrica (Oslo, Norway : 1992)* **102**, 857-862 (2013).
- 19
- 20 41. Gelissen IC, Nguyen HL, Tiao DK, Ayoub R, Aslani P, Moles R. Statin use in Australian children: a
- 21 retrospective audit of four pediatric hospitals. *Paediatric drugs* **16**, 417-423 (2014).
- 22
- 23 42. Vuorio A, *et al.* Statins for children with familial hypercholesterolemia. *The Cochrane database of*
- 24 *systematic reviews* **7**, Cd006401 (2017).
- 25
- 26